Top Bottom
Dan.com
Dynadot

Jordon M.

Established Member
Impact
380
Ok, so, let's see if anyone else has some of the same confusions when it comes to investing into Big Pharma brandable domain names.

Example: Pharmaceutical - We see commercials all the time for new drugs hitting the market claiming to heal, fix, or suppress something. Each of these products has a unique brandable, pronounceable word, most times, not having any relation to the scientific ingredients,

A brandable domain investor that follows the above market decide to sweep up 50 domains for a potential upcoming drug that hasn't been named yet, outside of it's scientific ingredient list.

All 50 miss the mark and the new drug rolls out with a hand-reg name in far left field.

The same investor dumps and then reups with a different 50 in far left field for the next drug rolling out.

All 50 miss the mark again and the newest drug rolls out in the far right field.

How do you narrow down your big pharma investments to be more targeted and increase the odds of interest being in your favor?

It seems that big pharma may purposely avoid anything already owned and uses registration checks to grab whatever is available instead of spending more for the perfect one already owned.

Have you ever sold one?
If so, what was your experience?
 

ultradog

Established Member
Impact
679
Your chances of being able to convince a drug company to buy a name are very low, because their first priority has to be to follow FDA rules in naming. These rules are many and complex. The company may select a name only to have it rejected by the government.

Years back I looked into the growing weird and weirder name choices in new brands for drugs, and posted somewhere about it. It seems the rules for naming of drugs include so many odd restrictions that now companies will go find a weird name instead of choosing a good-sounding name.

Good-sounding names will too often violate one rule or another. Among the things pharma companies must watch for are names that are too close to an already-existing drug — and this will likely be to avoid medical mistakes, rather than copyrights. One odd thing I remember the FDA considers is how the name looks when written in cursive.
 
Name Worth